Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL435839 | 0.90 | FFAR1 (0.80) | FFAR1GNA15 | |
| SCHEMBL17386171 | 0.90 | FFAR1 (0.80) | FFAR1GNA15 | |
| SCHEMBL3980603 | 0.90 | FFAR1 (1.00) | FFAR1GNA15 | |
| SCHEMBL3518855 | 0.90 | FFAR1 (1.00) | FFAR1GNA15 | |
| SCHEMBL3520994 | 0.90 | FFAR1 (1.00) | FFAR1GNA15 | |
| SCHEMBL13118039 | 0.90 | FFAR1 (0.77) | FFAR1GNA15 | |
| SCHEMBL13118284 | 0.84 | FFAR1 (0.72) | FFAR1GNA15 | |
| SCHEMBL19436258 | 0.82 | FFAR1 (0.68) | FFAR1GNA15 | |
| SCHEMBL13435422 | 0.82 | FFAR1 (0.57) | FFAR1GNA15 | |
| SCHEMBL19244288 | 0.81 | FFAR1 (0.84) | FFAR1GNA15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3443957-B1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | LIMINAL BIOSCIENCES LTD (GB) | 2020-11-25 | — | — | EP | disclosed |
| EP-3443957-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | PROMETIC PHARMA SMT LIMITED (GB) | 2019-02-20 | — | — | EP | disclosed |
| EP-2632452-B1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | PROMETIC PHARMA SMT LTD (GB) | 2018-09-26 | — | — | EP | disclosed |
| US-9439882-B2 | Compounds and compositions for the treatment of cancer | PROMETIC BIOSCIENCES INC. (CA) | 2016-09-13 | — | — | US | disclosed |
| US-20150313856-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | PROMETIC PHARMA SMT LIMITED (GB) | 2015-11-05 | — | — | US | disclosed |
| US-9114118-B2 | Compounds and compositions for the treatment of cancer | PROMETIC BIOSCIENCES INC. (CA) | 2015-08-25 | — | — | US | disclosed |
| EP-2632452-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | ProMetic BioSciences Inc. (CA) | 2013-09-04 | — | — | EP | disclosed |
| US-20130217645-A1 | Compounds and Compositions for the Treatment of Cancer | PROMETIC BIOSCIENCES INC. (CA) | 2013-08-22 | — | — | US | disclosed |
| WO-2012097427-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | PROMETIC BIOSCIENCES INC. (CA) | 2012-07-26 | — | — | WO | disclosed |
| WO-2009055932-A1 | SUBSTITUTED PHENYLPROPIONIC ACIDS AS STIMULATORS OF HEMATOPOIESIS AND ERYTHROPOIESIS | PROMETIC BIOSCIENCES INC. (CA) | 2009-05-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130217645-A1 | Compounds and Compositions for the Treatment of Cancer | DCK, TOP2B, TOP2A | FFAR1 3574/4885GNA15 1866/4885 |
| US-20150313856-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | DCK, TOP2B, TOP2A | FFAR1 3574/4885GNA15 1866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.